Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 10 INDUSTRY 8 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Somatostatinoma 5 Kidney Neoplasms 5 Adrenocortical Carcinoma 5 Insulinoma 4 Glucagonoma 4 Gastrinoma 4 Carcinoma, Islet Cell 4 Thyroid Neoplasms 3 Thyroid Carcinoma, Anaplastic 3 Thyroid Cancer, Papillary 3 Squamous Cell Carcinoma of Head and Neck 3 Sarcoma 3 Salivary Gland Neoplasms 3 Pheochromocytoma 3 Neuroendocrine Tumors 3 Head and Neck Neoplasms 3 Carcinoma, Medullary 3 Adenocarcinoma, Follicular 3 Vipoma 2 Sarcoma, Synovial 2 Sarcoma, Endometrial Stromal 2 Pituitary Neoplasms 2 Ovarian Neoplasms 2 Neurofibrosarcoma 2 Neoplasms 2 Neoplasm Metastasis 2 Malignant mesenchymal tumor 2 Liposarcoma 2 Leiomyosarcoma 2 Histiocytoma, Malignant Fibrous 2

Interventions

telotristat ethyl 1 lanreotide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

NETWORK × Serotonin Syndrome × Endocrine × Clear all

NCT04065165 2020-02-05

TELEFIRST

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Withdrawn

Carcinoid Heart Disease, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡